Clinical trial of laboratory testing for immune response induced by COVID-19 vaccine
Not Applicable
- Conditions
- Coronavirus disease 2019 (COVID-19)
- Registration Number
- JPRN-UMIN000043350
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Interim analysis results up to 2 weeks after the third vaccination (peak phase) were published in Vaccines 2022, 10(7), 1050; https://doi.org/10.3390/vaccines10071050'. We have clarified the behavior of long-term humoral and cell-mediated immunity against SARS-CoV-2 and characterized the antibody assay system. We are currently analyzing the behavior in the third/fourth vaccination (booster).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 51
Inclusion Criteria
Not provided
Exclusion Criteria
1.Those who cannot tolerate multiple blood draws due to thin blood vessels. 2.Those who have difficulty collecting blood and have strong pain. 3.Those with a history of vasovagal reflex. 4.Those who have already been vaccinated with COVID-19 vaccine.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SARS-CoV-2 antibody titers (neutralizing antibody titers and nucleocapsid-antibody, spike-antibody by multiple reagents): humoral immunity
- Secondary Outcome Measures
Name Time Method